- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.03. | NEUREN PHARMACEUTICALS LIMITED: Notification of cessation of securities - NEU | 1 | ASX | ||
| 23.03. | NEUREN PHARMACEUTICALS LIMITED: Update - Notification of buy-back - NEU | - | ASX | ||
| 12.03. | NEUREN PHARMACEUTICALS LIMITED: Update - Notification of buy-back - NEU | 1 | ASX | ||
| 09.03. | NEUREN PHARMACEUTICALS LIMITED: Update - Notification of buy-back - NEU | - | ASX | ||
| 06.03. | NEUREN PHARMACEUTICALS LIMITED: Change of Director's Interest Notice - J Basile | 1 | ASX | ||
| 03.03. | NEUREN PHARMACEUTICALS LIMITED: Update - Notification of buy-back - NEU | 1 | ASX | ||
| NEUREN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 03.03. | Why Capstone Copper, Life360, Neuren, and St George Mining shares are falling today | 54 | The Motley Fool Australia | ||
| 03.03. | Neuren Partner Acadia To Seek EMA Re-Examination After CHMP Rejects Trofinetide For Rett Syndrome | 1 | RTTNews | ||
| 02.03. | NEUREN PHARMACEUTICALS LIMITED: Acadia confirms plan to request CHMP re-examination | - | ASX | ||
| 27.02. | Neuren Pharmaceuticals Limited Announces Retreat In Full Year Bottom Line | 13 | RTTNews | ||
| 27.02. | Neuren shares dip after FY25 result. Here's what stood out | 1 | The Motley Fool Australia | ||
| 27.02. | NEUREN PHARMACEUTICALS LIMITED: Investor presentation, 27 February 2026 | 1 | ASX | ||
| 27.02. | Neuren Pharmaceuticals earnings: Profits up, pipeline builds in 2025 | 3 | The Motley Fool Australia | ||
| 26.02. | NEUREN PHARMACEUTICALS LIMITED: 2025 royalty income A$65m, profit after tax A$30m | - | ASX | ||
| 26.02. | NEUREN PHARMACEUTICALS LIMITED: Appendix 4E and 2025 full year accounts | - | ASX | ||
| 26.02. | Neuren Shares Surge on Royalty Income Boost | 5 | Finance News Network | ||
| 26.02. | Why Neuren shares are jumping more than 6% today | 3 | The Motley Fool Australia | ||
| 26.02. | NEUREN PHARMACEUTICALS LIMITED: Acadia reports DAYBUE net sales for 2025 and 2026 guidance | 2 | ASX | ||
| 26.02. | Neuren Pharmaceuticals shares paused ahead of company announcement | 1 | The Motley Fool Australia | ||
| 25.02. | NEUREN PHARMACEUTICALS LIMITED: Pause in Trading | - | ASX |
1 2 3 4 Weiter >>
66 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANTHERA PHARMACEUTICALS | 17,260 | -1,60 % | Santhera Pharmaceuticals Holding AG: Handelsupdate für das Geschäftsjahr 2025 | Ad-hoc-Mitteilung gemäss Art. 53 KR
AGAMREE setzt starke Geschäftsentwicklung fort und erzielt Umsatzwachstum von 98%
Pratteln, Schweiz, 12. März 2026 - Santhera Pharmaceuticals (SIX: SANN)... ► Artikel lesen | |
| CITIUS PHARMACEUTICALS | 0,838 | 0,00 % | Citius Pharmaceuticals, Inc. - 8-K, Current Report | ||
| MILESTONE PHARMACEUTICALS | 1,385 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST (etripamil) Nasal Spray for the Treatment of PSVT | FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic... ► Artikel lesen |
Das Unternehmen NEUREN PHARMACEUTICALS LIMITED kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,40 % bei einem Aktienkurs von 7,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUREN PHARMACEUTICALS LIMITED finden Sie auf Wallstreet Online.